Publikationen in Zusammenarbeit mit Forschern von National Cancer Institute (10)

2024

  1. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

2021

  1. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

2020

  1. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

2016

  1. Assessment of minimal residual disease in myeloma and the need for a consensus approach

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 21-25

  2. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 26-30

  3. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 31-39

2015

  1. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development

    Nature Medicine, Vol. 21, Núm. 10, pp. 1199-1208

2014

  1. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

    American Journal of Hematology

2007

  1. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas

    Blood, Vol. 109, Núm. 1, pp. 271-280